<DOC>
	<DOCNO>NCT00747006</DOCNO>
	<brief_summary>The purpose study determine , favorable dose TI Inhalation Powder establish either type 1 2 patient , base average diabetic meal , patient 's favorable dose use safely , regardless change meal carbohydrate content . Patients randomly assign various carbohydrate load ( 0 % , 50 % , 100 % , 150 % 200 % ) . The 100 % carbohydrate load determine base upon standard insulin dose normal meal .</brief_summary>
	<brief_title>Safety Efficacy TechnosphereÂ® Insulin Inhalation Powder ( TI Inhalation Powder ) When Optimal Dose Taken With Varied Carbohydrate Intake</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Clinical diagnosis type 1 type 2 diabetes mellitus Fasting Plasma Glucose ( FPG ) 80 , 140 mg/dL glycated hemoglobin ( A1C ) &gt; 6.5 % &lt; = 10.0 % . Body mass index ( BMI ) &lt; = 40 kg/m2 Nonsmokers ( never smoke former smoker [ = 6 month since cessation ] ) urine cotinine level &lt; = 100 ng/dL Forced expiratory volume 1 second ( FEV1 ) = 70 % Third National Health Nutrition Examination Survey ( NHANES III ) Predicted ; prebronchodilator FEV1 percentage force vital capacity ( FEV1/Forced vital capacity ( FVC ) ) = 70 % For subject type 2 diabetes mellitus : Currently receive oral diabetic treatment basal insulin +/ oral diabetic treatment History chronic obstructive pulmonary disease ( COPD ) , clinically proven asthma , and/or clinically important pulmonary disease confirm pulmonary function test ( PFT ) and/or radiologic finding Elevated liver function test ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 3 time normal reference range bilirubin &gt; 1.5 time reference range ) Previous use Exubera ; use Symlin ( pramlintide acetate ) and/or Byetta ( exenatide ) within past 12 week Unstable diabetes control evidence severe complication diabetes mellitus ( ie , autonomic neuropathy ) Exposure investigational product ( ) past 12 week For subject type 2 diabetes mellitus : In subject take metformin , serum creatinine &gt; 1.4 mg/dL female subject &gt; 1.5 mg/dL male subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>